MicroRNA therapeutics in cardiovascular disease models

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 185-203

  Dangwal, Seema ^a   Thum, Thomas ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Animal models; Cardiovascular disease; MicroRNAs; MiRNA therapeutics

Indexed keywords

MICRORNA;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; EXPERIMENTAL CARDIOVASCULAR DISEASE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IN VIVO GENE TRANSFER; IN VIVO STUDY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SOCIOECONOMICS; VASCULAR DISEASE; VIRAL GENE THERAPY;

ANIMALS; APOPTOSIS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC THERAPY; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84891848945     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135957     Document Type: Review

References (86)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. 2013. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127:e6-245
2. Gaziano TA. 2005. Cardiovascular disease in the developing world and its cost-effective management. Circulation 112:3547-53
3. Ambros V. 2001. microRNAs: tiny regulators with great potential. Cell 107:823-26
4. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97
5. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, et al. 2009. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 324:1710-13
6. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, et al. 2011. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123:282-91
7. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, et al. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 13:613-18
8. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, et al. 2009. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460:705-10
9. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, et al. 2010. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328:1570-73
10. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980-84
11. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, et al. 2007. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116:258-67
12. Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-40
13. da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, et al. 2010. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 12:1220-27
14. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. 2006. A signature pattern of stressresponsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 103:18255-60
15. Thum T. 2012. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol. Med. 4:3-14
16. Quiat D, Olson EN. 2013. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J. Clin. Investig. 123:11-18
17. van Rooij E, Olson EN. 2012. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11:860-72
18. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, et al. 2011. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ. Res. 109:1115-19
19. 2+ overload and cell death. J. Clin. Investig. 122:1222-32
20. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, et al. 2013. MicroRNA-34a regulates cardiac ageing and function. Nature 495:107-10
21. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, et al. 2010. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 122:2378-87
22. van Rooij E, Purcell AL, Levin AA. 2012. Developing microRNA therapeutics. Circ. Res. 110:496-507
23. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, et al. 2011. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124:1537-47
24. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, et al. 2011. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43:371-78
25. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, et al. 2012. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 110:71-81
26. Levin AA. 1999. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489:69-84
27. Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, et al. 2001. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296:898-904
28. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, et al. 2001. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296:890-97
29. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. 2005. Silencing of microRNAs in vivo with 'antagomirs.' Nature 438:685-89
30. Broderick JA, Salomon WE, Ryder SP, Aronin N, Zamore PD. 2011. Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA 17:1858-69
31. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, et al. 2011. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404-7
32. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, et al. 2011. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Investig. 121:2921-31
33. Grünweller A, Hartmann RK. 2007. Locked nucleic acid oligonucleotides: the next generation of antisense agents? Bio Drugs 21:235-43
34. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, et al. 2010. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Investig. 120:3912-16
35. Ebert MS, Sharp PA. 2007. Roles for microRNAs in conferring robustness to biological processes. Cell 149:515-24
36. Horie T, Ono K, Nishi H, Iwanaga Y, Nagao K, et al. 2009. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem. Biophys. Res. Commun. 389:315-20
37. Sayed D, Rane S, Lypowy J, He M, Chen IY, et al. 2008. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell 19:3272-82
38. Haraguchi T, Ozaki Y, Iba H. 2009. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 37:e43
39. Xie J, Ameres SL, Friedline R, Hung JH, Zhang Y, et al. 2012. Long-term, efficient inhibition of micro-RNA function in mice using rAAV vectors. Nat. Methods 9:403-9
40. Yang Y, Ago T, Zhai P, Abdellatif M, Sadoshima J. 2011. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ. Res. 108:305-13
41. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, et al. 2009. MicroRNA-145, a novel smoothmuscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 105:158-66
42. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, et al. 2010. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 107:810-17
43. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, et al. 2009. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2:ra81
44. Zhang Y, Liu D, Chen X, Li J, Li L, et al. 2010. Secreted monocyticmiR-150 enhances targeted endothelial cell migration. Mol. Cell 39:133-44
45. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, et al. 2012. Animal models of heart failure: a scientific statement from the American Heart Association. Circ. Res. 111:131-50
46. Kinugawa S, Post H, Kaminski PM, Zhang X, Xu X, et al. 2003. Coronary microvascular endothelial stunning after acute pressure overload in the conscious dog is caused by oxidant processes: the role of angiotensin II type 1 receptor and NAD(P)H oxidase. Circulation 108:2934-40
47. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, et al. 1990. Effect ofβ-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82:473-83
48. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, et al. 2012. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3:1078
49. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, et al. 2009. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 105:585-94
50. da CostaMartins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, et al. 2008. Conditional Dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118:1567-76
51. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, et al. 2011. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124:720-30
52. Thum T, Chau N, Bhat B, Gupta SK, Linsley PS, et al. 2011. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J. Clin. Investig. 121:461-62; author reply 462-63
53. Teerlink JR, Pfeffer JM, Pfeffer MA. 1994. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ. Res. 75:105-13
54. Shan J, Kushnir A, Betzenhauser MJ, Reiken S, Li J, et al. 2010. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J. Clin. Investig. 120:4388-98
55. Ji R, Cheng Y, Yue J, Yang J, Liu X, et al. 2007. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res. 100:1579-88
56. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, et al. 2009. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 23:2166-78
57. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, et al. 2008. microRNA-133a regulates cardiomyocyte proliferation and suppresses smoothmuscle gene expression in the heart. Genes Dev. 22:3242-54
58. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. 2011. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler. Thromb. Vasc. Biol. 32:361-69
59. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. 2007. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:575-79
60. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. 2008. Dysregulation of micro-RNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. USA 105:13027-32
61. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, et al. 2009. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82:21-29
62. Bostjancic E, Zidar N, Glavac D. 2009. MicroRNA microarray expression profiling in human myocardial infarction. Dis. Markers 27:255-68
63. Kumarswamy R, Lyon AR, Volkmann I, Mills AM, Bretthauer J, et al. 2012. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur. Heart J. 33:1067-75
64. Wang Z, Lu Y, Yang B. 2011. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc. Res. 89:710-21
65. Cardin S, Guasch E, Luo X, Naud P, LeQuang K, et al. 2012. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ. Arrhythm. Electrophysiol. 5:1027-35
66. Adam O, Lohfelm B, Thum T, Gupta SK, Puhl SL, et al. 2012. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res. Cardiol. 107:278
67. Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. 2013. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 33:449-54
68. Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, et al. 2009. Acquisition of the contractile phenotype by murine arterial smoothmuscle cells depends on the Mir143/145 gene cluster. J. Clin. Investig. 119:2634-47
69. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, et al. 2012. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 126:S81-90
70. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, et al. 2008. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 15:261-71
71. Zhu H, Fan GC. 2012. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc. Res. 94:284-92
72. Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, et al. 2013. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 128:1066-75
73. Bang C, Fiedler J, Thum T. 2012. Cardiovascular importance of the microRNA-23/27/24 family. Microcirculation 19:208-14
74. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. 2011. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc. Natl. Acad. Sci. USA 108:8287-92
75. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. 2011. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J. Exp. Med. 208:549-60
76. Volkmann I, Kumarswamy R, Pfaff N, Fiedler J, Dangwal S, et al. 2013. microRNA-mediated epigenetic silencing of Sirtuin1 contributes to impaired angiogenic responses. Circ. Res. 113:997-1003
77. Ouyang YB, Stary CM, Yang GY, Giffard R. 2013. microRNAs: innovative targets for cerebral ischemia and stroke. Curr. Drug Targets 14:90-101
78. Zhang L, Chopp M, Liu X, Teng H, Tang T, et al. 2012. Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the Toll-like receptor signaling pathway. Arterioscler. Thromb. Vasc. Biol. 32:1856-64
79. Liu ME, Liao YC, Lin RT, Wang YS, Hsi E, et al. 2013. A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis. Atherosclerosis 228:161-67
80. Shi H, Sun BL, Zhang J, Lu S, Zhang P, et al. 2013. miR-15b suppression of Bcl-2 contributes to cerebral ischemic injury and is reversed by sevoflurane preconditioning. CNS Neurol. Disord. Drug Targets 12:381-91
81. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, et al. 2010. MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. J. Biol. Chem. 285:29223-30
82. Rottiers V, Näär AM. 2012. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 13:239-50
83. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y. 2013. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 33:178-85
84. -/- mice. J. Am. Heart Assoc. 1:e003376
85. Marquart TJ, Wu J, Lusis AJ, Baldan A. 2013. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 33:455-58
86. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, et al. 2013. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368:1685-94